Mark Gurney (Tetra Therapeutics)

Ahead of cru­cial PhII read­out, Sh­iono­gi lines up an op­tion to buy out biotech part­ner and its non-amy­loid Alzheimer's drug

With the make-or-break re­sults that will prove lit­tle Tetra right — or wrong — about its Alzheimer’s drug just around the cor­ner, part­ner Sh­iono­gi is putting it­self in a po­si­tion to act quick­ly should the Phase II tri­al come back pos­i­tive.

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.